Therapeutics for Neurodevelopmental Disorders
Millions of children are born every year with Neurodevelopmental disorders (NDDs) like epilepsy, intellectual disability, severe autism and motor disorders. We are accelerating drug discovery for NDDs using our unique collection of patient-derived neuronal models.
At Neurolentech we pave the road for drug development for patients with neurodevelopmental disorders. Using our world-leading expertise in neurodevelopmental disorders alongside our proprietary platform for developing robust patient-derived neuronal cell model systems, we identify new potential druggable targets for treating epilepsy, severe autism and intellectual disability indications.
Neurolentech exists for the purpose of developing new treatments for neurodevelopmental diseases; providing relief and less severe outcomes for patients and their families.
We envision a world where effective treatment options exist for every patient with a neurodevelopmental disease.
We work in close partnerships with clinicians and patient foundations to speed up the progress of drug discovery for neurodevelopmental disorders. For example, we are partnering with the Tess Foundation to discover new treatments for SLC13A5 epilepsy. The Tess Foundation has showcased a number of their member families and affected individuals as examples of the profound impact the disease has on the lives of patients.
Aubrey was the true definition of a superhero. Despite all of the daily challenges, Aubrey smiled through it all. She was our little warrior since the day she was bornRead more Aubrey and other SLC13A5 superheroes on the Tess Foundation website. READ MORE